Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Linguistic features of spontaneous speech transcribed and analyzed by NLP techniques show significant differences between controls and pathological states (not only eD but also MCI) and seems to be a promising approach for the identification of preclinical stages of dementia.
|
30483116 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (<sup>18</sup>F-flortaucipir and <sup>18</sup>F-florbetaben), MRI, and neuropsychologic tests.
|
30926651 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Of 181 subjects, 66 were normal (clinical dementia rating [CDR] = 0), 88 had MCI (CDR = 0.5), and 27 had dementia (CDR = 1 or above).
|
29089886 |
2017 |
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
150 individuals with ET (109 Normal Cognition (ET-NC group), and 30 with MCI and 11 dementia (ET-CI group)) completed self-ratings and objective assessments of memory, language, and executive functioning.
|
28477687 |
2017 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
208 participants remained normal and 60 developed cognitive decline, consistent with a diagnosis of MCI or dementia.
|
25212916 |
2014 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A high prevalence of MCI or dementia was observed in the elderly population.
|
28769097 |
2017 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multivariate model based on the Disease State Index classifier incorporated the available baseline tests to predict progression to MCI or dementia over time.
|
30619929 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to cognitive function, the patients were divided into a group of normal cognitive function, a mild cognitive impairment group (MCI group) and a dementia group.
|
28956423 |
2017 |
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AD dementia risk in late MCI, in early MCI, and in subjective memory impairment.
|
23375567 |
2014 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition.
|
29318973 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additional subgroup analyses (MCI versus dementia, Aβ-positive versus Aβ-negative subjects) were performed.
|
30636731 |
2019 |
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After 5 years of motor symptoms, 24% of participants met the criteria for MCI and 69% for dementia.
|
31678902 |
2020 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Age (hazard ratio (HR) 1.05 per year, 95% CI: 1.01-1.08, p = 0.007), presence of MCI status (HR 3.40, 95% CI: 1.97-6.92, p < 0.001), MTA (HR 1.71 per point, 95% CI: 1.26-2.32, p = 0.001), and SVD score (HR 1.23 per point, 95% CI: 1.20-1.48, p = 0.030) at baseline were independent predictors for dementia conversion in these patients.
|
28318355 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although PD-MCI is a risk factor for developing Parkinson's disease dementia there is evidence to suggest that PD-MCI might consist of distinct subtypes with different pathophysiologies and prognoses.
|
25814509 |
2015 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings indicate that evaluating executive functions with the IFS can be valuable for the identification of MCI, a high-risk group for dementia, and for differentiating this condition from healthy aging and AD.
|
31504056 |
2019 |
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 200 outpatients with dementia and MCI whose NGF SNP rs6330 genotype was identified, those with A-MCI (n = 35) and early-stage AD (n = 67) were recruited and divided into three groups according to genotype (C/C: n = 58, C/T: n = 39, T/T: n = 5).
|
22301435 |
2011 |
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 200 outpatients with dementia and MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, based on the representative BDNF functional polymorphism Val66Met.
|
22699449 |
2012 |
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among 215 outpatients with dementia and MCI, 155 with mild AD (n = 108) or A-MCI (n = 47) were recruited and divided into three genotypic groups based on the representative NT-3 functional polymorphisms rs6332 and rs6489630.
|
23075484 |
2012 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia.
|
29446123 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
At follow-up, 8 out of 41 patients (19.5%) with MCI had progressed to dementia, 8 patients (19.5%) had improved to normal levels of cognitive functioning, 25 patients (61%) had remained stable within the MCI group.
|
9850913 |
1998 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carriers were more likely to receive scores of 0.5 or higher on the CDR (p < 0.001), and a clinical diagnosis of either MCI or dementia (p = 0.004).
|
22442429 |
2012 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCM demonstrates corneal nerve fiber loss, which is associated with a decline in cognitive function and functional independence in patients with MCI and dementia.
|
31019993 |
2019 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive decline (defined as the incidence of either Parkinson's disease mild cognitive impairment [PD-MCI] or dementia [PDD], diagnosed according to published criteria and blinded to genotype) was studied as the primary outcome.
|
28869277 |
2018 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive function was assessed using two computer-based questionnaires (touch panel-type dementia assessment scale [TDAS] and mild cognitive impairment [MCI] screen).
|
28345266 |
2017 |
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF Apo-E levels were associated with longitudinal cognitive decline, MCI conversion to dementia, and gray matter atrophy rate in total tau/Aβ1-42 ratio and APOE genotype-adjusted analyses.
|
24385135 |
2014 |